Law.com Subscribers SAVE 30%

Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.

Drug & Device News

By ALM Staff | Law Journal Newsletters |
August 02, 2014

Allergan Says Kickback Allegations Are 'Baseless'

In its response to whistleblower claims filed in the U.S. District Court for the Eastern District of Pennsylvania, Allergan ' the pharmaceuticals company best known for producing Botox ' says allegations that it illegally induced ophthalmologists to prescribe its eye-care products are “baseless.” Among the company's eye-care products is the well-advertised prescription medication Restasis. The complaint was brought by relators Dr. Herbert Nevyas and Dr. Anita Nevyas-Wallace, both Pennsylvania ophthalmologists, who claim that “[a]s a direct result of defendant's improper practices, federal and state health insurance programs … have been caused to pay false or fraudulent claims for reimbursement of the defendant's prescription drugs that resulted from defendant's illegal kickbacks.” In support of its motion to dismiss, Allergan countered, in papers filed June 30, that the relators had advanced a “peculiar and baseless theory of liability, where the primary allegation is that Allergan openly advertised and charged eye care practices in the amount of several hundreds of dollars on an annual basis for product and practice management consultative services and that this program somehow constitutes an unlawful kickback scheme.”

This premium content is locked for LJN Newsletters subscribers only

  • Stay current on the latest information, rulings, regulations, and trends
  • Includes practical, must-have information on copyrights, royalties, AI, and more
  • Tap into expert guidance from top entertainment lawyers and experts

For enterprise-wide or corporate acess, please contact Customer Service at [email protected] or 877-256-2473

Read These Next
The DOJ's Corporate Enforcement Policy: One Year Later Image

The DOJ's Criminal Division issued three declinations since the issuance of the revised CEP a year ago. Review of these cases gives insight into DOJ's implementation of the new policy in practice.

The DOJ's New Parameters for Evaluating Corporate Compliance Programs Image

The parameters set forth in the DOJ's memorandum have implications not only for the government's evaluation of compliance programs in the context of criminal charging decisions, but also for how defense counsel structure their conference-room advocacy seeking declinations or lesser sanctions in both criminal and civil investigations.

Use of Deferred Prosecution Agreements In White Collar Investigations Image

This article discusses the practical and policy reasons for the use of DPAs and NPAs in white-collar criminal investigations, and considers the NDAA's new reporting provision and its relationship with other efforts to enhance transparency in DOJ decision-making.

Bankruptcy Sales: Finding a Diamond In the Rough Image

There is no efficient market for the sale of bankruptcy assets. Inefficient markets yield a transactional drag, potentially dampening the ability of debtors and trustees to maximize value for creditors. This article identifies ways in which investors may more easily discover bankruptcy asset sales.

Compliance Officers: Recent Regulatory Guidance and Enforcement Actions and Mitigating the Risk of Personal Liability Image

This article explores legal developments over the past year that may impact compliance officer personal liability.